Journal of Diabetes Investigation最新文献

{"title":"Response to the comment of Wasti on “Association between severity of diabetic complications and risk of cancer in middle-aged patients with type 2 diabetes”","authors":"Yao-Hsien Tseng, Pau-Chung Chen","doi":"10.1111/jdi.70034","DOIUrl":"10.1111/jdi.70034","url":null,"abstract":"<p>Dear Dr. Hotta,</p><p>We appreciate Wasti's thoughtful comment<span><sup>1</sup></span> on our research recently published in the Journal of Diabetes Investigation. In this study, we demonstrated a positive association between the severity of diabetic complications and cancer risk in middle-aged patients with type 2 diabetes<span><sup>2</sup></span>. We carefully evaluated concerns related to cohort selection, measurement of complication severity, and potential confounding factors, and we appreciate the opportunity to clarify these issues.</p><p>Our study focused on participants aged 40–65 with newly diagnosed type 2 diabetes who received antidiabetic treatment. By excluding younger individuals—who may have type 1 or atypical early-onset diabetes—and elderly patients with multiple comorbidities and prolonged disease durations, we established a more homogeneous cohort. It was particularly crucial to exclude patients who did not use medication, as untreated individuals are more likely to be misclassified or to represent only very mild diabetes managed solely by diet. We minimized misclassification bias and ensured that our cohort consisted exclusively of patients with clinically active, pharmacologically treated diabetes. This careful selection strategy offers a more comprehensive understanding of the incidence of cancer following the initial diabetes diagnosis<span><sup>3, 4</sup></span>.</p><p>We measured the severity of diabetes complications using the adapted Diabetes Complications Severity Index (aDCSI), a validated tool for claims data that assigns scores across seven major complication categories. By updating the aDCSI annually as a time-dependent measure, we were able to track the cumulative and evolving effects of diabetes over time. This approach more accurately reflects the progression of disease burden and monitors changes in patient conditions even without direct clinical measures such as HbA1c. Although our dataset lacked comprehensive lifestyle information (e.g., body mass index, smoking status, or alcohol consumption), we adjusted for available proxies, including age, sex, income, urbanization, hypertension, hyperlipidemia, and medication usage. While these adjustments may not eliminate residual confounding, they provide a robust basis for the validity of our findings.</p><p>The overall hazard ratio of roughly 1.2 may appear modest; however, it signifies a substantial risk elevation given the high prevalence of both diabetes and cancer. Notably, our subgroup analysis revealed that younger patients—particularly those aged 40–44—experienced an almost 1.8-fold increased risk, underscoring our work's significant public health implications. To mitigate potential surveillance bias and reverse causality, cancer outcomes were obtained from a national registry that requires pathological confirmation, and we imposed a one-year lag period to exclude cancers present at the time of diabetes diagnosis. Furthermore, we utilized a competing risk","PeriodicalId":51250,"journal":{"name":"Journal of Diabetes Investigation","volume":"16 5","pages":"965-966"},"PeriodicalIF":3.1,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jdi.70034","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143707937","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter to the Editor in Response to “Association between severity of diabetic complications and risk of cancer in middle-aged patients with type 2 diabetes”","authors":"Syeda Aamna Wasti","doi":"10.1111/jdi.70028","DOIUrl":"10.1111/jdi.70028","url":null,"abstract":"<p>Dear Editor,</p><p>I recently read the article titled “Association between severity of diabetic complications and risk of cancer in middle-aged patients with type 2 diabetes”<span><sup>1</sup></span>, which provides valuable insights on the relation between the risk of cancer development and diabetes severity, being the first to address this association. However, I believe there are several limitations that could be highlighted to strengthen the findings further.</p><p>Firstly, while the study adjusts for a variety of known confounders, it does not account for other potential unmeasured variables like physical activity, diet, changes in treatment guidelines through the study period, or genetic predispositions to both diabetes and cancer, which could influence the observed associations. Secondly, the study uses data from the Taiwan National Health Insurance Research Database, limiting generalizability as it primarily reflects the Taiwanese population. Factors like healthcare systems, genetic differences, and lifestyle factors may cause variable associations between cancer risk and diabetes in different populations; hence, replication in more diverse populations could help validate the conclusions. Reliance on a single database affects the robustness of the study.</p><p>Additionally, since this is a retrospective and observational study, it does find a relationship between the two factors but does not definitively conclude that one factor causes the other, that is it does prove an association but not a cause-and-effect relationship. Moreover, even though steps have been taken to reduce reverse causality, there may still be some patients with undiagnosed or early-stage cancer that were not identified and could influence the course of diabetes complications.</p><p>The study also has some potential biases, including selection bias—data on patients who are unable to access healthcare, with non-medication managed diabetes or undiagnosed early complications may be missing, or data on those who are lost to follow-up may differ from those who remained in the study, leading to overestimation or underestimation of cancer risk in the wider population—and medication use—the study does account for it; however, patients with more severe diabetic complications may be prescribed more aggressive treatments, which can influence cancer risk. There could also be a potential overlap between cancer and diabetes treatments that is not addressed, confounding the results. Additionally, exclusion of patients diagnosed with cancer within the first year of their diabetes diagnosis could result in survival bias, impacting generalizability.</p><p>Furthermore, the follow-up period for this study is 13 years, which may not capture the influence of diabetes complications on cancers that take longer to manifest; a longer follow-up would provide more comprehensive insights. The current study also does not consider various subtypes of a particular cancer; the risk associated with ","PeriodicalId":51250,"journal":{"name":"Journal of Diabetes Investigation","volume":"16 5","pages":"964"},"PeriodicalIF":3.1,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jdi.70028","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143655538","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Overcoming barriers in continuous glucose monitoring: Challenges and future directions in diabetes management","authors":"Hung-Chun Chen,&nbsp;Yi-Hsuan Lai,&nbsp;Yi-Der Jiang","doi":"10.1111/jdi.70019","DOIUrl":"10.1111/jdi.70019","url":null,"abstract":"<p>Recent updates on the efficacy of continuous glucose monitoring (CGM) and a critical examination of the current challenges in its implementation were summarized. The barriers to widespread adoption of this technology should be addressed, considering the impact of different cultural contexts. The strategies to overcome these obstacles and the benefits of CGM for future glucose management will be discussed.</p>","PeriodicalId":51250,"journal":{"name":"Journal of Diabetes Investigation","volume":"16 5","pages":"769-774"},"PeriodicalIF":3.1,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jdi.70019","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143623048","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Two cases of neonatal hyperglycemia caused by a homozygous COQ9 stop-gain variant","authors":"Russell Donis,&nbsp;Maryam Al Badi,&nbsp;Nadia Alhashmi,&nbsp;Andrew T Hattersley,&nbsp;Sarah E Flanagan,&nbsp;Elisa De Franco","doi":"10.1111/jdi.70022","DOIUrl":"10.1111/jdi.70022","url":null,"abstract":"<p>Neonatal diabetes mellitus (NDM) is a monogenic condition diagnosed &lt;6 months of age with &gt;40 genetic causes. International guidelines recommend referral for genetic testing immediately after diagnosis since the genetic result guides clinical management. We used next-generation sequencing to identify a homozygous pathogenic variant, p.(Arg244*), in <i>COQ9</i> in 2 individuals referred for NDM testing. Both had insulin-treated hyperglycemia, severe structural brain defects, dysmorphic features, and lactic acidosis. Recessive loss-of-function variants in <i>COQ9</i> cause Coenzyme Q10 deficiency-5, a multi-system mitochondrial disease, with 7 cases reported. Neonatal hyperglycemia has not been reported in any of these cases but has been described for two other Coenzyme Q10 disorders caused by variants in <i>COQ2</i> and <i>COQ4</i>. Our report shows that individuals with <i>COQ9</i>-related disease can present with neonatal hyperglycemia, expanding the clinical spectrum of this disorder. We recommend the inclusion of <i>COQ9</i>, as well as <i>COQ2</i> and <i>COQ4</i>, to gene panels used for NDM testing.</p>","PeriodicalId":51250,"journal":{"name":"Journal of Diabetes Investigation","volume":"16 5","pages":"959-963"},"PeriodicalIF":3.1,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jdi.70022","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143584051","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Revisiting the causal impact of lipid traits on metabolic dysfunction-associated fatty liver disease: Insights from a multidimensional plasma lipid profile","authors":"Fang Xie,&nbsp;Wenkai Zheng,&nbsp;Jing Chen,&nbsp;Chuanxia Yao,&nbsp;Cong Li,&nbsp;Li Tang,&nbsp;Ping Li,&nbsp;Shanzhong Tan","doi":"10.1111/jdi.14413","DOIUrl":"10.1111/jdi.14413","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>Recent advancements in plasma lipidomes genome-wide association studies data have enhanced our understanding of lipid categories, significantly improving risk assessments for metabolic dysfunction-associated fatty liver disease (MAFLD) beyond traditional lipid biomarkers.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and Methods</h3>\u0000 \u0000 <p>This study utilized Mendelian randomization (MR) to assess the causal relationships between 179 lipid species across 13 subclasses and MAFLD, primarily using the Wald ratio and IVW methods. Corrections were made using false discovery rate (FDR), supplemented by Bayesian colocalization analysis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Elevated levels of genetically predicted phosphatidylcholine (16:0_16:1) [OR_{Wald ratio} = 2.638, 95% CI 1.557–4.469, <i>P</i> = 3.11 × 10⁻⁴], phosphatidylcholine (16:1_18:0) (OR_{Wald ratio} = 2.644, 95% CI 1.559–4.486, <i>P</i> = 3.11 × 10⁻⁴), triacylglycerol (46:2) (OR_{Wald ratio} = 2.515, 95% CI 1.524–4.153, <i>P</i> = 3.11 × 10⁻⁴), and triacylglycerol (48:2) (OR_IVW = 1.863, 95% CI 1.300–2.669, <i>P</i> = 6.95 × 10⁻⁴) were significantly associated with increased MAFLD risk, with rs1260326 within the GCKR gene playing a crucial role. Colocalization analysis indicated that in significant evidences, the posterior probability for hypothesis 4 was over 80%, identifying rs780093 as a shared causal variant. Additionally, 16 suggestive evidences were identified.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The study confirmed the significant role of specific lipid molecules in influencing MAFLD risk, providing new scientific bases and potential therapeutic targets for future treatment strategies.</p>\u0000 </section>\u0000 </div>","PeriodicalId":51250,"journal":{"name":"Journal of Diabetes Investigation","volume":"16 5","pages":"917-928"},"PeriodicalIF":3.1,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jdi.14413","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143571842","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical features among adult-onset type 1 diabetes, distribution of subtypes, and differences in probable and definite slowly progressive insulin-dependent diabetes mellitus: A single hospital-based study over a 13-year period","authors":"Hiroko Takaike,&nbsp;Junnosuke Miura,&nbsp;Satoshi Takagi,&nbsp;Shota Mochizuki,&nbsp;Tetsuya Babazono","doi":"10.1111/jdi.70012","DOIUrl":"10.1111/jdi.70012","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>In Japan, type 1 diabetes (T1D) is classified into three subtypes based on its onset patterns; however, the proportion of each subtype remains unexplored. To elucidate the heterogeneity in adult-onset type 1 diabetes, we compared the frequencies of subtypes and clinical features by age at onset.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and Methods</h3>\u0000 \u0000 <p>This cross-sectional, observational, single-institution study included 482 individuals (161 male) with T1D. The clinical and laboratory data, including glutamic acid decarboxylase autoantibodies, were extracted from the medical records.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The number of adults who developed T1D decreased with age. Among all patients, 62% (<i>n</i> = 299) had acute-onset T1D, 27% (<i>n</i> = 131) had slowly progressive T1D (SPIDDM), and 11% (<i>n</i> = 52) had fulminant T1D. The proportion of patients with fulminant T1D was approximately equivalent in all age groups; however, the percentage of patients with acute-onset T1D decreased from 78% in the 20–29 age group to 27% in the 70–79 age group. The proportion of patients with SPIDDM significantly increased with age, ranging from 16% in the 20–29 age group to 60% in the 70–79 age group. Among patients with SPIDDM, the prevalence of definite SPIDDM was 89%, and this prevalence did not differ based on the age at onset. Body mass index and C-peptide levels among patients with probable SPIDDM were significantly higher than those among patients with definite SPIDDM.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The proportion of adult-onset T1D subtypes differed according to the age at onset. In adult-onset T1D, some etiological differences may be based on age at onset.</p>\u0000 </section>\u0000 </div>","PeriodicalId":51250,"journal":{"name":"Journal of Diabetes Investigation","volume":"16 5","pages":"952-958"},"PeriodicalIF":3.1,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jdi.70012","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143571760","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Construction of a metabolic-immune model for predicting the risk of diabetic nephropathy and study of gut microbiota","authors":"Mengting Dai,&nbsp;Jianbo Wu,&nbsp;Zhaoyang Ji,&nbsp;Ping Chen,&nbsp;Chengchen Yang,&nbsp;Jialu Luo,&nbsp;Pengfei Shan,&nbsp;Mingzhi Xu","doi":"10.1111/jdi.14401","DOIUrl":"10.1111/jdi.14401","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>This study conducts a comprehensive analysis of the relative impact of risk factors for diabetic nephropathy (DN) during disease progression, with a particular emphasis on the role of gut microbiota. We developed multiple predictive models trying to enhance the early identification of high-risk patients in clinical practice.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and Methods</h3>\u0000 \u0000 <p>We collected data from type 2 diabetes mellitus patients, categorizing them by renal function for comparison. Logistic regression identified risk factors for DN, and we developed nomogram and random forest risk prediction models. Finally, we analyzed the correlations among these factors.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Compared to patients with diabetes alone, those with DN have a longer disease duration, characterized by abdominal obesity, hypertension, chronic inflammation, activation of the complement system, and declining renal function, along with a significant reduction in Bifidobacterium and Enterobacterium. Patients with macroalbuminuria exhibit a higher male prevalence, as well as elevated blood pressure and lipid levels, and poorer renal function. Increased waist-to-hip ratio, systolic blood pressure, urea, neutrophil-to-lymphocyte ratio, and complement C3, along with decreased Enterobacterium and albumin, have been identified as significant risk factors for DN. The nomogram model developed based on these findings demonstrates good predictive capacity. And the establishment of the random forest model further underscores the importance of the aforementioned indicators. Additionally, significant correlations were observed among obesity, inflammation, blood pressure, lipid levels, and gut microbiota.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Dysbiosis, metabolic disorders, and chronic inflammation play key roles in the progression of DN and may serve as new targets for future prevention and treatment strategies.</p>\u0000 </section>\u0000 </div>","PeriodicalId":51250,"journal":{"name":"Journal of Diabetes Investigation","volume":"16 5","pages":"863-873"},"PeriodicalIF":3.1,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jdi.14401","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143603171","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to Commentary on ‘Diminished levels of insulin-like growth factor-1 may be a risk factor for peripheral neuropathy in type 2 diabetes patients’","authors":"Jingyi Zhong,&nbsp;Xiaopu Lin,&nbsp;Xiaobin Zheng,&nbsp;Yanting Zhou,&nbsp;Haishan Huang,&nbsp;Lingling Xu","doi":"10.1111/jdi.70017","DOIUrl":"10.1111/jdi.70017","url":null,"abstract":"<p>We truly value the readers' meticulousness and conscientiousness. Future studies will incorporate these instructive recommendations to further investigate diabetic neuropathy.</p>","PeriodicalId":51250,"journal":{"name":"Journal of Diabetes Investigation","volume":"16 4","pages":"762"},"PeriodicalIF":3.1,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jdi.70017","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143539725","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ginsenoside Rg1 inhibits angiogenesis in diabetic retinopathy through the miR-100-3p/FBXW7/c-MYC molecular axis","authors":"Liping Xue,&nbsp;Min Hu,&nbsp;Yadi Li,&nbsp;Qin Zhu,&nbsp;Guanglong Zhou,&nbsp;Xiaofan Zhang,&nbsp;Yuan Zhou,&nbsp;Jieying Zhang,&nbsp;Peng Ding","doi":"10.1111/jdi.70016","DOIUrl":"10.1111/jdi.70016","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aims/Introduction</h3>\u0000 \u0000 <p>Ginsenoside Rg1 is an active ingredient found mainly in ginseng that has a variety of pharmacological effects, such as hypoglycemic, antioxidant, and anti-inflammatory effects, and it inhibits vascular formation. In this study, we explored the effect of ginsenoside Rg1 on angiogenesis in diabetic retinopathy (DR) on the basis of its ability to inhibit angiogenesis and the specific molecular mechanism involved.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and Methods</h3>\u0000 \u0000 <p>We induced an in vivo model of diabetes by injection of 55 mg/kg streptozotocin (STZ) into the abdominal cavity of SD rats daily for 3 days. Moreover, human retinal microvascular endothelial cells (HRMECs) were treated with 30 mmol/L glucose for 24 h to construct a high-glucose (HG) cell model in vitro. The expression of related genes and proteins was detected by RT-qPCR and Western blotting. HRMECs and retinal damage were evaluated by CCK-8, scratch, tube formation assays, and HE staining.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>In this study, Rg1 inhibited HG-induced angiogenesis of HRMECs and inhibited STZ-induced vascular leakage and capillary degeneration in vivo, alleviating the progression of DR. Mechanistically, Rg1 upregulated the expression of FBXW7 by inhibiting miR-100-3p, thereby promoting the ubiquitination and degradation of c-MYC, inhibiting HG-induced HRMECs proliferation, migration, invasion, and angiogenesis, and improving the development of DR.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Overall, our study demonstrates that ginsenoside Rg1 can inhibit DR angiogenesis via the miR-100-3p/FBXW7/c-MYC molecular axis. These findings provide a novel idea for the treatment of DR and provide an experimental basis for further research on the application of Rg1 in the treatment of DR.</p>\u0000 </section>\u0000 </div>","PeriodicalId":51250,"journal":{"name":"Journal of Diabetes Investigation","volume":"16 5","pages":"791-806"},"PeriodicalIF":3.1,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jdi.70016","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143539724","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictive value of biliverdin reductase-A and homeostasis model assessment of insulin resistance on mild cognitive impairment in patients with type 2 diabetes","authors":"Li Shen,&nbsp;Xiaole Wei,&nbsp;Nan Wang,&nbsp;Haorui Lv,&nbsp;Jing Huang,&nbsp;Xiaoyan Zhou,&nbsp;Aifang Cheng,&nbsp;Changjiang Ying","doi":"10.1111/jdi.70020","DOIUrl":"10.1111/jdi.70020","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aims/Introduction</h3>\u0000 \u0000 <p>To investigate the predictive value of the biliverdin reductase-A (BVR-A) and the homeostasis model assessment for insulin resistance (HOMA-IR) on mild cognitive impairment (MCI) in patients with type 2 diabetes mellitus, and to establish a nomogram model.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and Methods</h3>\u0000 \u0000 <p>This study included 140 patients with type 2 diabetes mellitus. Based on Montreal Cognitive Assessment (MoCA) scores, participants were categorized into the normal cognitive function (T2DM-NCF) group (65 cases) and the mild cognitive impairment (T2DM-MCI) group (75 cases). Multivariate logistic regression analysis was performed to identify the factors associated with MCI in patients with type 2 diabetes mellitus. A nomogram prediction model was developed using R software for the selected factors, and its predictability and accuracy were verified.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Compared with the T2DM-NCF group, subjects with MCI were older, had a longer duration of diabetes, higher HOMA-IR, lower BVR-A, lower cognitive scores, and lower education levels (all <i>P</i> &lt; 0.05). Multivariate logistic regression analysis showed that duration of diabetes (OR = 1.407, 95% CI: 1.163–1.701), HOMA-IR (OR = 1.741, 95% CI: 1.197–2.53), and BVR-A (OR = 0.528, 95% CI: 0.392–0.712) were significantly associated with the development of MCI in patients with type 2 diabetes mellitus. The C-index of the nomogram was 0.863 (95% CI: 0.752–0.937).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Our findings suggest that BVR-A and HOMA-IR are significantly associated with the development of MCI in patients with type 2 diabetes mellitus. The nomogram incorporating BVR-A and HOMA-IR aids in predicting the risk of developing MCI in these patients.</p>\u0000 </section>\u0000 </div>","PeriodicalId":51250,"journal":{"name":"Journal of Diabetes Investigation","volume":"16 5","pages":"936-944"},"PeriodicalIF":3.1,"publicationDate":"2025-03-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jdi.70020","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143536147","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}